Literature DB >> 18344044

Refinement of diagnosis and disease classification in psychiatry.

Yves Lecrubier1.   

Abstract

Knowledge concerning the classification of mental disorders progressed substantially with the use of DSM III-IV and IDCD 10 because it was based on observed data, with precise definitions. These classifications a priori avoided to generate definitions related to etiology or treatment response. They are based on a categorical approach where diagnostic entities share common phenomenological features. Modifications proposed or discussed are related to the weak validity of the classification strategy described above. (a) Disorders are supposed to be independent but the current coexistence of two or more disorders is the rule; (b) They also are supposed to have stability, however anxiety disorders most of the time precede major depression. For GAD age at onset, family history, biology and symptomatology are close to those of depression. As a consequence broader entities such as depression-GAD spectrum, panic-phobias spectrum and OCD spectrum including eating disorders and pathological gambling are taken into consideration; (c) Diagnostic categories use thresholds to delimitate a border with normals. This creates "subthreshold" conditions. The relevance of such conditions is well documented. Measuring the presence and severity of different dimensions, independent from a threshold, will improve the relevance of the description of patients pathology. In addition, this dimensional approach will improve the problems posed by the mutually exclusive diagnoses (depression and GAD, schizophrenia and depression); (d) Some disorders are based on the coexistence of different dimensions. Patients may present only one set of symptoms and have different characteristics, evolution and response to treatment. An example would be negative symptoms in Schizophrenia; (e) Because no etiological model is available and most measures are subjective, objective measures (cognitive, biological) and genetics progresses created important hopes. None of these measures is pathognomonic and most appear to be related to risk factors especially at certain periods when associated with environmental events. One of the major aims for a classification of patients is to identify groups to whom a best possible therapeutic strategy can be proposed. Drugs may improve fear extinction while the genetic and/or acquired avoidance may be called phobia. The basic mechanism and or the corresponding phenotype should appear in the classification. Progresses in early identification of disturbances by taking into account all the information available (prodromal symptoms, cognitive, biological, imaging, genetic, family information) are crucial for the future therapeutic strategy: prevention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18344044     DOI: 10.1007/s00406-007-1003-0

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  40 in total

1.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

Review 2.  The influence of comorbidity on the prevalence of suicidal behaviour.

Authors:  Y Lecrubier
Journal:  Eur Psychiatry       Date:  2001-11       Impact factor: 5.361

3.  Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk.

Authors:  C B Pedersen; P B Mortensen
Journal:  Arch Gen Psychiatry       Date:  2001-11

4.  Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey.

Authors:  R C Kessler; C B Nelson; K A McGonagle; J Liu; M Swartz; D G Blazer
Journal:  Br J Psychiatry Suppl       Date:  1996-06

5.  A twin study of genetic relationships between psychotic symptoms.

Authors:  Alastair G Cardno; Frühling V Rijsdijk; Pak C Sham; Robin M Murray; Peter McGuffin
Journal:  Am J Psychiatry       Date:  2002-04       Impact factor: 18.112

6.  Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.

Authors:  Avshalom Caspi; Karen Sugden; Terrie E Moffitt; Alan Taylor; Ian W Craig; HonaLee Harrington; Joseph McClay; Jonathan Mill; Judy Martin; Antony Braithwaite; Richie Poulton
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

7.  Limbic-frontal circuitry in major depression: a path modeling metanalysis.

Authors:  D A Seminowicz; H S Mayberg; A R McIntosh; K Goldapple; S Kennedy; Z Segal; S Rafi-Tari
Journal:  Neuroimage       Date:  2004-05       Impact factor: 6.556

8.  Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

Authors:  L L Judd; H S Akiskal; J D Maser; P J Zeller; J Endicott; W Coryell; M P Paulus; J L Kunovac; A C Leon; T I Mueller; J A Rice; M B Keller
Journal:  J Affect Disord       Date:  1998-09       Impact factor: 4.839

9.  Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning.

Authors:  Christoph Kellendonk; Eleanor H Simpson; H Jonathan Polan; Gaël Malleret; Svetlana Vronskaya; Vanessa Winiger; Holly Moore; Eric R Kandel
Journal:  Neuron       Date:  2006-02-16       Impact factor: 17.173

10.  Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.

Authors:  Stefan G Hofmann; Alicia E Meuret; Jasper A J Smits; Naomi M Simon; Mark H Pollack; Katherine Eisenmenger; Michael Shiekh; Michael W Otto
Journal:  Arch Gen Psychiatry       Date:  2006-03
View more
  15 in total

1.  Exploring the role of a nicotine quantity-frequency use criterion in the classification of nicotine dependence and the stability of a nicotine dependence continuum over time.

Authors:  Orla McBride; David R Strong; Christopher W Kahler
Journal:  Nicotine Tob Res       Date:  2010-01-15       Impact factor: 4.244

2.  Reliability and validity of the Symptoms of Depression Questionnaire (SDQ).

Authors:  Paola Pedrelli; Mark A Blais; Jonathan E Alpert; Richard C Shelton; Rosemary S W Walker; Maurizio Fava
Journal:  CNS Spectr       Date:  2014-10-02       Impact factor: 3.790

Review 3.  From categorical to dimensional diagnostics: deficiency-oriented versus person-centred diagnostics.

Authors:  Michael Musalek; Oliver Scheibenbogen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

Review 4.  Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology.

Authors:  André R Brunoni; Laura Tadini; Felipe Fregni
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

5.  Animal models of virus-induced neurobehavioral sequelae: recent advances, methodological issues, and future prospects.

Authors:  Marco Bortolato; Sean C Godar
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-05-18

6.  Familiality of major depressive disorder and patterns of lifetime comorbidity. The NEMESIS and GenMood studies. A comparison of three samples.

Authors:  Maaike Verhagen; Annemarie van der Meij; Barbara Franke; Wilma A M Vollebergh; Ron de Graaf; Jan K Buitelaar; Joost G E Janzing
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-24       Impact factor: 5.270

Review 7.  Removing obstacles in neuroscience drug discovery: the future path for animal models.

Authors:  Athina Markou; Christian Chiamulera; Mark A Geyer; Mark Tricklebank; Thomas Steckler
Journal:  Neuropsychopharmacology       Date:  2008-10-01       Impact factor: 7.853

8.  Creating a map of psychiatric patients based on psychopathological symptom profiles.

Authors:  Samy Egli; Michael Riedel; Hans-Jürgen Möller; Anton Strauss; Damian Läge
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-01-22       Impact factor: 5.270

9.  Moving towards ICD-11 and DSM-V: Concept and evolution of psychiatric classification.

Authors:  P K Dalal; T Sivakumar
Journal:  Indian J Psychiatry       Date:  2009 Oct-Dec       Impact factor: 1.759

10.  BCL9 and C9orf5 are associated with negative symptoms in schizophrenia: meta-analysis of two genome-wide association studies.

Authors:  Chun Xu; Nagesh Aragam; Xia Li; Erika Cynthia Villla; Liang Wang; David Briones; Leonora Petty; Yolanda Posada; Tania Bedard Arana; Grace Cruz; ChunXiang Mao; Cynthia Camarillo; Brenda Bin Su; Michael A Escamilla; KeSheng Wang
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.